|Mr. Richard A. Gonzalez||Chairman & CEO||7.42M||19.91M||1954|
|Mr. Robert A. Michael||Vice Chairman & Pres||3.82M||N/A||1970|
|Ms. Laura J. Schumacher||Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.||4.18M||13.28M||1963|
|Mr. Jeffrey Ryan Stewart||Exec. VP & Chief Commercial Officer||3.25M||N/A||1969|
|Mr. Scott T. Reents||Sr. VP & CFO||N/A||N/A||1967|
|Dr. Azita Saleki-Gerhardt Ph.D.||Exec. VP of Operations||N/A||N/A||1963|
|Dr. Thomas J. Hudson||Sr. VP of R&D and Chief Scientific Officer||N/A||N/A||1962|
|Ms. Elizabeth Shea||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Timothy J. Richmond||Exec. VP & Chief HR Officer||N/A||N/A||1966|
|Mr. Henry O. Gosebruch||Exec. VP & Chief Strategy Officer||N/A||N/A||1973|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc.’s ISS governance QualityScore as of 1 September 2022 is 8. The pillar scores are Audit: 10; Board: 5; Shareholder rights: 9; Compensation: 3.